Haisco Inks Licensing, Research Deal with Eli Lilly

Haisco Pharmaceutical Group entered a licensing and research collaboration with Eli Lilly and Co. (NYSE: LLY) on June 1, 2026, the companies announced. Financial terms and the specific therapeutic focus of the partnership were not disclosed. Under the deal, Haisco will receive an undisclosed upfront payment and may be eligible for milestone payments and royalties on future net sales. The collaboration aims to leverage Haisco’s discovery capabilities and Lilly’s global development and commercial infrastructure. The agreement marks Haisco’s latest tie-up with a major multinational drugmaker, expanding its external partnership portfolio. No further details were immediately available.